Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chiglitazar Add-On to SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Nationwide, Multicenter Registry Study (C-STAR)

NCT07580638 is registered in ClinicalTrials.gov with Chipscreen Biosciences, Ltd. as lead sponsor.

NCT NCT07580638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07580638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chiglitazar Add-On to SGLT-2 Inhibitors in Patients With Type 2 Diabetes: A Nationwide, Multicenter Registry Study (C-STAR)
Lead sponsor
Chipscreen Biosciences, Ltd.
Phase
Observational
Overall status
Not yet recruiting
Start date
July 18, 2026
Completion date
July 18, 2028
Enrollment
3,550 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

t2dm (type 2 diabetes mellitus)